Cigna (CI) Downgraded by Barclays, Price Target Cut to $304
Published on 5/31/2026

AI Summary
Summarized by AI from the source belowOn May 26, Barclays downgraded Cigna (CI) from Overweight to Equal Weight and reduced its price target from $310 to $304. The downgrade reflects concerns around Cigna's limited earnings upside potential due to its lower exposure to government insurance programs, alongside uncertainties regarding a pharmacy benefit manager transition. Additionally, Barclays highlighted risks related to commercial membership losses and potential job cuts related to AI. This situation contrasts with UBS's recent rating increase, raising Cigna's target to $400, indicating differing outlooks among analysts.
Get the free market brief
Top stories and analysis, summarized. No spam, unsubscribe anytime.
Related News

Earnings
Vanguard Small-Cap Value ETF (VBR) and Fed Rate Hike Impact
Sep 1

Earnings
HealthEquity (HQY) Reports 8% Revenue Growth in Q2 Fiscal 2027
Sep 1

Earnings
Napco Security Technologies (NSSC) Reports $55.8M Record Revenue
Sep 1

Earnings
Berkshire's Stock Value Analysis: Is It Cheap? Insights from Abel
Sep 1